# A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)

> **NCT04530994** · — · APPROVED_FOR_MARKETING · sponsor: **Mirum Pharmaceuticals, Inc.**

## Conditions studied

- Alagille Syndrome

## Interventions

- **DRUG:** maralixibat

## Key facts

- **NCT ID:** NCT04530994
- **Lead sponsor:** Mirum Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2021-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04530994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04530994, "A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04530994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*